home / stock / cdmop / cdmop news

CDMOP News and Press, Avid Bioservices Inc. 10.50% Series E Convertible Preferred Stock From 11/30/23

Stock Information
Company Name: Avid Bioservices Inc. 10.50% Series E Convertible Preferred Stock
Stock Symbol: CDMOP
Market: NASDAQ
Website: avidbio.com
Menu
CDMOP CDMOP Quote CDMOP Short CDMOP News CDMOP Articles CDMOP Message Board
Get CDMOP Alerts

News, Short Squeeze, Breakout and More Instantly...
CDMOP - Avid Bioservices to Report Financial Results for Second Quarter of Fiscal Year 2024 After Market Close on December 7, 2023

TUSTIN, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announc...
CDMOP - Avid Bioservices Partners With California Institute for Regenerative Medicine (CIRM) to Provide CDMO Services for Cell and Gene Therapy (CGT) Programs

TUSTIN, Calif., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and phar...

CDMOP - Avid Bioservices Completes Construction of New, World-Class Cell and Gene Therapy Development and Manufacturing Facility

Newly Launched CGMP Manufacturing Suites Undergoing Final Environmental Monitoring and Performance Qualification with Grand Opening Planned for January 2024 Completion of CGT Facility Brings Company’s Total Revenue Generating Capacity to up to Approximately $400 Million Annually ...

CDMOP - Avid Bioservices to Participate in RBC Capital Markets Virtual CDMO Conference

TUSTIN, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pha...
CDMOP - Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2023

-- Recorded First Quarter Revenue of $37.7 Million -- -- Signed $36 Million in Net New Business Orders Resulting in a Backlog of $189 Million -- -- Cell and Gene Therapy Facility Expansion Remains on Schedule for Opening by End of Calendar Q3 2023 -- TUSTIN, Calif., Sept. ...

CDMOP - Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2024 After Market Close on September 7, 2023

TUSTIN, Calif., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announc...

CDMOP - Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2023

-- Fourth Quarter and Full Year Revenue of $39.8 Million and $149.3 Million, Respectively, Both Represent a Record-High Achievement -- -- Signed $55 Million in Net New Business Orders Resulting in a Record-High Backlog of $191 Million -- -- Mammalian Cell Manufacturing and Process...
CDMOP - Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2023 After Market Close on June 21, 2023

TUSTIN, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announc...

CDMOP - Avid Bioservices to Participate in RBC Capital Markets Global Healthcare Conference

TUSTIN, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharm...

CDMOP - Avid Bioservices Unveils Completed Mammalian Cell Facilities Expansion Providing Significantly Increased Capacity for Existing and Future Customers

Company to Host Open House to Celebrate Official Launch of Newest CGMP Mammalian Cell Manufacturing Suites within Myford Facility First Customer Project in Newly Expanded Capacity to Kick-Off This Month Company Also Announces Completion of Mammalian Cell Process Development Capa...
Previous 10 Next 10